Catalysts from several late-stage projects including those from Astrazeneca, Sanofi, Allakos and Celldex aim to shake up the market.
But how different is ACU193 really?
But subgroup analyses from Trailblazer-Alz 2 show that earlier is better for donanemab.
The latest deal focuses on in vivo Crispr editing for sickle cell disease, and follows last year’s cancer collaboration.
The Belgian group is riding high as investors look for future successes in other inflammatory diseases.
A convincing hit puts approval, and potentially partnerships, on the table.